Home > Boards > US OTC > Biotechs > Sangamo Biosciences Inc. (SGMO)

Is this accurate? I cannot seem to find

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ofthegreenes Member Profile
 
Followed By 15
Posts 1,370
Boards Moderated 1
Alias Born 11/30/16
160x600 placeholder
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire (US) - 6/21/2019 9:16:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/18/2019 5:03:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:03:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:14:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:10:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:09:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:08:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:07:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:05:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 5:43:08 PM
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences PR Newswire (US) - 5/15/2019 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 8:02:59 AM
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference PR Newswire (US) - 5/10/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 4:39:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 4:19:31 PM
Sangamo Therapeutics Reports First Quarter 2019 Financial Results PR Newswire (US) - 5/8/2019 4:01:00 PM
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast PR Newswire (US) - 5/1/2019 4:01:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/25/2019 4:36:32 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 4:34:05 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 4/18/2019 6:48:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/17/2019 4:46:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2019 7:28:53 PM
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy PR Newswire (US) - 4/15/2019 4:01:00 PM
Potential Blockbuster Gene Therapy Programs to Watch in 2019 NetworkNewsWire - 4/10/2019 8:45:00 AM
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to ... PR Newswire (US) - 4/8/2019 4:01:00 PM
ofthegreenes   Monday, 10/23/17 09:35:10 PM
Re: Triple9 post# 289
Post # of 327 
Is this accurate? I cannot seem to find it. I like this tid bit.
Traders may be relying in part on technical stock analysis. Sangamo Therapeutics (SGMO) currently has a 14-day Commodity Channel Index (CCI) of -143.65. Despite the name, CCI can be used on other investment tools such as stocks. The CCI was designed to typically stay within the reading of -100 to +100. Traders may use the indicator to determine stock trends or to identify overbought/oversold conditions. A CCI reading above +100 would imply that the stock is overbought and possibly ready for a correction. On the other hand, a reading of -100 would imply that the stock is oversold and possibly set for a rally.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist